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Abstract Patients with atypical haemolytic uremic syndrome
(aHUS) with a mutation in the gene encoding membrane
cofactor protein (CD46) are known to have a better prognosis
than those with mutations in factor H (CFH) or factor I
(CFI), but a small number of the former still proceed to end-
stage renal failure. Plasma therapy (PE) is the recommended
approach to treat both acute episodes and prevent recurrences
in aHUS, but studies have yet to show PE efficacy in aHUS
associated with a CD46 mutation. The factors determining
failure to treatment are not clear and may be related to the
mutation involved or to insufficient treatment. Our experi-
ence of PE in a family of three sisters with CFH-associated
aHUS suggests that intensive and prophylactic PE allows
renal function to be maintained in both native kidneys and
allografts. The success of this strategy has led us to use it in
all cases of aHUS. Here, we describe the effect of this
strategy in a child with aHUS and a CD46 mutation. The
initial episode was treated with daily PE, resulting in the
recovery of renal function. However, over the next 4 years,
there was a progressive decline in renal function to end-stage
renal failure, with evidence of an on-going thrombotic
microangiopathy despite continuous prophylactic PE.
Prophylactic PE does not influence the natural course of
aHUS and CD46 mutation.
Keywords Atypical HUS .CD46 mutation .
Membrane cofactor protein . Plasma exchange
Introduction
Approximately 60% of patients with atypical haemolytic
uremic syndromes (aHUS) have mutations in the genes
encoding the complement proteins factor H (CFH), factor I
(CFI), membrane cofactor protein (CD46), factor B (CFB)
and factor C3 (C3) [1–5]. Among the total number of aHUS
patients screened to date for the CFH, CFI and membrane
cofactor protein (MCP) mutations, 20% have a mutation of
CFH, 15% of MCP and 5–10% of CFI [3]. When patients
are stratified according to their underlying mutation, an
important “genotype–phenotype” correlation is observed.
The prognosis in patients with either a CFH or CFI
mutation is poor, with approximately70% developing end-
stage renal failure (ESRF). In contrast, over 80% of patients
with a CD46 mutation remain dialysis-independent [1–3].
Although plasma therapy (PE) appears to be beneficial in
patients with CFH and CFI mutations, a positive effect in
patients with a CD46 mutation is doubtful [2, 3]. In the
absence of controlled trials, the analysis of well-
documented case reports remains the primary means of
assessing the value of PE. To that effect, we have had the
unique opportunity to follow over a period of 10 years a
family of three sisters (two of whom are monozygotic
twins) with CFH-associated aHUS [6]. Analysis of the
natural history of the disease in this family suggests that the
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strategy of plasma therapy is crucial and that only intensive
and prophylactic PE are able to maintain renal function in
both native kidneys and allografts. The success of this
strategy has led us to use it in all cases of aHUS. Here, we
describe in this article the effect of this strategy in a child
with CD46-associated aHUS.
Case report
This previously healthy 3-year-old boy presented with renal
failure, haemolytic anaemia, thrombocytopenia and hyper-
tension in the absence of a preceding diarrhoeal illness. The
diagnosis of aHUS was confirmed by renal biopsy, which
showed diffuse glomerular basement membrane thickening
and splitting with subendothelial fibrinoid deposition.
Endothelium swelling associated with wall thickening in
some arteries was also visible. Neither glomerulosclerosis
nor tubular atrophy was observed. The clinical evolution is
outlined in Fig. 1. Dialysis (initially hemodialysis and
subsequently peritoneal dialysis) was started because of salt
and water retention. The patient was never anuric, and the
maximum plasma creatinine level was 270µmol/L. Dialysis
was stopped after 2 months when the plasma creatinine was
110µmol/L. Two weeks after presentation, the patient
developed seizures secondary to malignant hypertension
and was admitted to a paediatric intensive care unit where
daily PE was commenced (40 ml/kg per session of fresh
frozen plasma). After a further 2 weeks, his clinical
condition improved, his platelet count normalized and
plasma lactate dehydrogenase (LDH) stabilized at slightly
increased levels. Eight weeks after presentation, he was
transferred to our centre for creation of an arterio-venous
shunt and chronic prophylactic PE. The frequency of PE
was reduced to three times a week until the plasma
creatinine level returned to 47µmol/L (calculated creatinine
clearance according to Schwartz: 90 ml/min per 1.73 m2)
5 months after presentation. The frequency of PE was then
reduced to twice weekly and then to once a week thereafter.
Of note, the plasma LDH values never normalized
completely. The plasma concentration of the complement
factors C3, C3d, C4, Factor B, AP 50 and CH 50 were
normal and remained so throughout the course of his
illness. Growth retardation was present until renal trans-
plantation. Hypertension was difficult to control until the
introduction of AII receptors blockers 6 months after
presentation. For the next 24 months, the glomerular
filtration rate (GFR), proteinuria and blood pressure
remained normal, and no hospitalization was needed. There
were many short episodes of absence which were treated
satisfactory with valproic acid and lamotrigine. Computed
tomography scanning showed no cerebral lesions. During
the third year after presentation, the plasma creatinine level
rose progressively from normal values to 127µmol/L
(calculated creatinine clearance 40 ml/min per 1.73 m2).
At the same time proteinuria developed (1.1 g/24 h) and the
blood pressure increased. The platelet count remained
normal despite continuously slightly increased LDH and
low haptoglobin plasma values, persisting until nephrecto-
my. A renal biopsy performed at that time showed
extensive global glomerulosclerosis affecting 50% of the
glomeruli. The previously mentioned abnormalities per-
sisted in the remaining glomeruli, but arteriolar lesions
were more widespread and there was diffuse tubular
atrophy. Renal function continued to slowly deteriorate.
Four years after initial presentation, the patient was
admitted with malignant hypertension (160/105 mmHg),
headaches, weight loss and malaise. Because of resistance
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Fig. 1 Effect of prophylactic
plasma exchanges in a patient
with membrane cofactor protein
mutation-related haemolytic
uremic syndrome. LDH: lactate
dehydrogenase
1758 Pediatr Nephrol (2009) 24:1757–1760
to antihypertensive therapy and despite the absence of
ESRF (plasma creatinine 250µmol/L), bilateral nephrecto-
my was performed and hemodialysis was started. There was
histological evidence of severe chronic thrombotic micro-
angiopathy in both kidneys. After nephrectomy, blood
pressure, plasma LDH and haptoglobin levels normalized,
and his general condition improved. Mutation screening of
CFH, CFI, C3 and CFB showed no abnormalities. Serum
factor H and factor I concentrations were 0.55 g/l (normal
range 0.35–0.59 g/l) and 49 mg/l (normal range 38–58 mg/l),
respectively. Mutation screening of CD46 showed a mis-
sense mutation in exon 11 (c.1058C>T, p.Ala353Val;
alternative syntax Ala304Val). The patient was homozy-
gous for the at risk C allele of CD46 c.4047T>C rs7144,
heterozygous for the at risk G allele of CD46 -652A>G
rs2796267 and homozygous for the at risk G allele of CD46
366A>G rs2796268. He was heterozygous for the at risk T
allele of CFH -332C>T rs3753394, heterozygous for the
at risk G allele of CFH c.2016A>G Q672Q rs3753396
and heterozygous for the at risk T allele of CFH c.2808G>T
E936D rs1065489. At 17 months after starting hemodial-
ysis, he received a cadaver renal transplant. Immunosup-
pression comprised prednisolone, low-dose cyclosporine,
mycophenolate mofetyl and basiliximab. Plasma therapy
was undertaken immediately prior to transplant, daily
during the first postoperative week and then stopped. He
did not relapse after transplantation, and the plasma
creatinine level 12 months post-transplant is 0.9 mg/dL
(80µmol/L).
Discussion
The patient described here was found to have a mutation
in the CD46 gene encoding membrane cofactor protein
(c.1058C>T, p.Ala353Val). This mutation has been de-
scribed previously in aHUS and is known to be function-
ally significant [7]. Of the three aHUS patients described
by Fang et al. [7], one developed ESRF. Because MCP is a
transmembrane molecule, its role is limited to the surface
of endothelial cells, and a CD46 mutation does not lead to
systemic complement dysregulation. The clinical implica-
tion of a CD46 mutation was analysed in two large series
of patients with aHUS [2, 3]. The conclusions drawn from
both studies were that CD46 mutations are associated with
a less severe course: no patients in the series reached
ESRF during the first episode [2], and 86% of patients
remained long-term dialysis-free [3]. Also, kidney trans-
plantation was generally successful [2, 3]. No beneficial
effect of plasma therapy on the prevention of ESRF could
be demonstrated in either series. In the French series [2],
favorable outcome occurred in eight (89%) of nine
episodes that were treated with plasma therapy and 15
(88%) of 17 untreated episodes; in the Italian series [3],
complete or partial remission (defined by healing of
hematological symptoms but persistence of renal sequelae)
was achieved in 91% of plasma-treated episodes but also in
100% of the non-treated episodes. However, the authors
could not exclude that in those patients who did not recover
spontaneously, plasma therapy failed because it was not
adequately administered. We have previously shown that
the success of plasma therapy in aHUS due to a CFH
mutation depends on the strategy used. Only intensive PE
at presentation followed by prophylactic treatment was
efficient in our earlier study [6]. Based on this result, we
used a similar approach in the management of this patient
with a CD46 mutation. In contrast to many previously
reported MCP-associated aHUS patients who have a
relapsing course with complete recovery after each
relapse, our patient had a single episode, which was
unusually severe (prolonged dialysis, severe hypertension)
but which resolved completely and was subsequently
followed by a progressive deterioration in renal function
without any clinical evidence of a significant acute
microangiopathy episode (no thrombopenia, no acute
hemolytic anemia). The presence of several at risk poly-
morphisms of CD46 and CFH may have enhanced the
pathogenic role of the CD46 mutation on the glomerular
endothelium. During the initial presentation, there was a
temporal relationship between plasma therapy and an
improvement in the clinical condition. However, this
improvement was slow, and it is questionable whether
this was a result of the treatment or a spontaneous
evolution. The delay before the initiation of PE may have
eventually played a role in this slow recovery. Subse-
quently, regular prophylactic PE was unable to prevent the
development of ESRF despite intensification in the
frequency of PE from weekly to daily. It is probable that
ongoing low-grade chronic thrombotic microangiopathy,
as evidenced by continuously slightly increased plasma
LDH plasma levels and a low haptoglobin until the time of
nephrectomy, had a significant role in the progression to
ESRF. The response to PE in this patient is, therefore, in
keeping with the suggestion from the authors of the two
previous studies [2, 3], that plasma therapy is unlikely to
be of therapeutic benefit in CD46 mutation-associated
aHUS, at least when given preventively. However,
because the results of mutation screening of complement
genes are not available for weeks or months after
presentation, all patients who present with aHUS should
be treated with PE. When the results of the mutation
screening eventually become known, these can guide both
the PE strategy to prevent relapses and the approach to
transplantation if and when patients reach ESRF—but
clear-cut recommendation concerning the treatment of
relapses cannot be given here.
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